Obesity Pipeline Market H1 Global Assessment of Therapeutics Development Companies Report 2017

Share this news:

Obesity – Pipeline (Metabolic Disorders) report identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The Pharmaceutical and Healthcare latest pipeline guide Obesity Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Browse Obesity Therapeutic Pipeline report has 96 Company Profiles, 154 Tables and 11 Figures, Spread across 495 Pages Report Available at http://www.rnrmarketresearch.com/obesity-pipeline-review-h1-2017-market-report.html .

Main companies of Obesity Therapeutic Pipeline - Abeome Corp, Adamas Pharmaceuticals Inc, Advinus Therapeutics Ltd, Aegis Therapeutics LLC, Akron Molecules AG, Alize Pharma SAS, Amabiotics SAS, Amgen Inc, Aoxing Pharmaceutical Company Inc, Arrowhead Pharmaceuticals Inc, AstraZeneca Plc, Asubio Pharma Co Ltd, Athersys Inc, Biophytis SAS, BioRestorative Therapies Inc, Biozeus, Boehringer Ingelheim GmbH, Braasch Biotech LLC, C3J Therapeutics Inc, Camurus AB, Carmot Therapeutics Inc, CohBar Inc, CoMentis Inc, Connexios Life Sciences Pvt Ltd, ConSynance Therapeutics Inc, Corium International Inc, Daiichi Sankyo Company Ltd, DiscoveryBiomed Inc, Eisai Co Ltd, Eli Lilly and Company, Esperion Therapeutics Inc, Eternygen GmbH, Evotec AG, F. Hoffmann-La Roche Ltd, FibroGen Inc, Genmedica Therapeutics SL, Gila Therapeutics Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Glucox Biotech AB, GTx Inc, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Hyundai Pharmaceutical Co Ltd, Immungenetics AG, Intarcia Therapeutics Inc, Ionis Pharmaceuticals Inc, Ixchel Pharma LLC, Jenrin Discovery Inc, Johnson & Johnson, Laboratorios Silanes SA de CV, Lead Discovery Center GmbH, Leading BioSciences Inc, Lotus Pharmaceutical Co Ltd, M Pharmaceutical Inc, Magnus Life Ltd, MedImmune LLC, Merck & Co Inc, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, NeuroNano Pharma Inc, NGM Biopharmaceuticals Inc, NIBEC, Nordic Bioscience A/S, Novartis AG,

Discount Available at http://www.rnrmarketresearch.com/contacts/discount?rname=1019680 (This report is available at upto 25% Discount till June 02nd 2017.)

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders). The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1019680

Table of Contents:
Introduction
Obesity - Overview
Obesity - Therapeutics Development
Obesity - Therapeutics Assessment
Obesity - Companies Involved in Therapeutics Development
Obesity - Drug Profiles
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix
List of Tables.
List of Figures.

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Call +1 888 391 5441 with your research requirements or email the details at sales@rnrmarketresearch.com

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: RnRMarketResearch.com
Website: http://www.rnrmarketresearch.com/obesity-pipeline-review-h1-2017-market-report.html

Release ID: 203531

CONTACT ISSUER
Name: Ritesh Tiwari
Email: Send Email
Organization: RnRMarketResearch.com
SUBSCRIBE FOR MORE